Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Per Kjaersgaard-Andersen, Vejle Hospital
ClinicalTrials.gov Identifier:
NCT00603083
First received: January 2, 2008
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

The purpose of this study is to determine whether the investigator standardized pain treatment plus local pain treatment is more effective than the investigator standardized pain treatment plus placebo in total hip arthroplasty.


Condition Intervention Phase
Pain, Postoperative
Drug: Ropivacaine, Ketorolac and Adrenalin
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Postoperative Pain Treatment in Total Hip Arthroplasty A Randomized Double-blinded Placebo-controlled Study to Assess the Effect of Local Analgesia

Resource links provided by NLM:


Further study details as provided by Vejle Hospital:

Primary Outcome Measures:
  • Pain score [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • Opioid Consumption [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pain score [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Opioid consumption [ Time Frame: 3 days ] [ Designated as safety issue: No ]
  • Postoperative Nausea and Vomiting (PONV) [ Time Frame: 3 days ] [ Designated as safety issue: No ]
  • Fatigue [ Time Frame: 3 days ] [ Designated as safety issue: No ]
  • Physical function [ Time Frame: 2 month ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: January 2008
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
Drug: Ropivacaine, Ketorolac and Adrenalin
The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
Other Names:
  • Naropin
  • Toradol
Placebo Comparator: B
This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
Drug: Placebo
This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
Other Name: Saline

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Scheduled for an uncemented unilateral Total Hip Replacement because of osteoarthritis
  • Willingness and possibility to follow the instructions of the study
  • 18 years or older
  • written informed consent and authority after it has been read and understood.

Exclusion Criteria:

  • Operation with anterior approach or using navigation
  • Do not understand or speech danish
  • Can not use the pain-score Numerical Rating Scale (NRS)
  • Special indications for Total Hip Replacement
  • Anaesthetized in general anaesthesia where a tube is demanded
  • Daily use of strong opioids, based on the investigators assessment
  • Fertile women
  • ASA-score: 3 and 4
  • Known allergy against the standardized pain treatment, the study drugs and placebo, Ropivacaine, Ketorolac, Adrenalin.
  • Treatment with Lithium, Dihydroergotamin, full anticoagulant treatment or MAO-inhibitor
  • Following illness:
  • Active gastric ulcer or earlier gastrointestinal bleeding, ulceration or perforation of any kind.
  • Suspicions of manifest gastrointestinal bleeding and/or cerebrovascular bleeding
  • Haemorrhagic diathesis
  • Coagulation disorder
  • Severe thrombocytopenia
  • Severe heart insufficiency
  • Severe risk of postoperative bleeding or delayed haemostatic
  • Myocardium hypertrophy or ischaemic heart disease
  • Hypertension
  • Hypovolemics
  • Anhydration
  • angiooedema
  • Asthma
  • Bronchospasm
  • Severe liver insufficiency
  • Rhinostenosis because of polyostotic
  • Narrow-angled glaucoma
  • Phaeochromocytoma
  • Low plasm-potassium
  • Thyreotoxicosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00603083

Locations
Denmark
Orthopaedic Department
Vejle, Denmark, 7100
Ortopaedic Department, Vejle Hospital
Vejle, Denmark, 7100
Sponsors and Collaborators
Vejle Hospital
Investigators
Principal Investigator: Per Kjaersgaard-Andersen, MD Ortopaedic Department, Vejle Hospital, Denmark
  More Information

No publications provided

Responsible Party: Per Kjaersgaard-Andersen, Per Kjaersgaard-Andersen MD, Vejle Hospital
ClinicalTrials.gov Identifier: NCT00603083     History of Changes
Other Study ID Numbers: EudraCT number 2007-003890-20, S-20070066
Study First Received: January 2, 2008
Last Updated: December 8, 2011
Health Authority: Denmark: Danish Medicines Agency
Denmark: The Ministry of the Interior and Health

Keywords provided by Vejle Hospital:
Hip Arthroplasty
Treatment Outcome
Local Anesthesia

Additional relevant MeSH terms:
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Pain
Signs and Symptoms
Ketorolac
Ketorolac Tromethamine
Ropivacaine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Anesthetics, Local
Anesthetics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on July 10, 2014